indicate that the elimination of NMP is governed by a saturable metabolism process. The Michaelis-Menten parameters estimated from plasma levels of unchanged NMP were 2 mM and 3.8 mg/h, respectively. Between 4 and 10% of the administered doses were excreted in the urine as unchanged NMP. Urinary clearance of NMP (0.03 to 0.07 ml/min) indicates intensive tubular reabsorption. 5-HNMP was the main urinary metabolite and accounted for 42 to 55% of the administered doses. Its maximal urinary excretion occurred between 4 and 6 h after administration of the three lowest doses and between 8 and 24 h for the two highest doses. Urinary clearance (0.9 to 1.3 ml/min) was compatible with renal elimination by simple glomerular filtration. (NMP 1 ) is a widely and increasingly used solvent. It dissolves most monomers and polymers and catalyzes many polymerization reactions. One of its main uses is in the petrochemical industry to extract aromatic oils. It is also used in the microelectronics fabrication industry to manufacture electronic capacitors and batteries. It is a solvent and cosolvent in pharmaceuticals, cosmetics, insecticides, herbicides, or in paint preparations. Finally, NMP is increasingly being used to remove graffiti (Akesson, 1994) .
N-Methyl-2-pyrrolidone
A recent study of NMP use in the microelectronics industry indicates that severe eye irritation and headaches can be expected at concentrations as low as 0.7 ppm, even for a short period of exposure (30 min) (Beaulieu and Schmerber, 1991) . After two days of working with NMP in a electrotechnical company, 10 of the 12 workers involved displayed acute irritant contact dermatitis of the hands (Leira et al., 1992) .
Acute toxicity is low. LD 50 in rabbits was 4 to 8 g/kg and 1.5 to 7 g/kg in rats after topical application. The LD 50 in mice after i.v., intraperitoneal, and oral administration was 3.5, 4.3, and 7.5 ml/kg, respectively. In rats, the LD 50 was 2.2, 2.4, and 3.8 ml/kg, respectively (Bartsch et al., 1976) .
In a subchronic feeding study on beagles (13 weeks old, 25 to 250 mg NMP/kg), no statistically significant treatment-related effects judged biologically meaningful were observed in any parameter of either the male or female animals exposed. However, a dose-dependent decrease in body weight and increase in platelet count correlated with increased megakaryocytes was observed. In addition, serum cholesterol in male rats decreased with increasing doses (Becci et al., 1983) .
Studies on reproductive toxicity have shown that NMP causes developmental toxicity at doses causing no or mild maternal toxicity (Hass et al., 1994; Solomon et al., 1995) . Cases of stillbirth after occupational exposure to NMP have been reported (Solomon et al., 1996; Bower, 1997) .
Animal studies have shown efficient absorption of NMP through the skin or gastrointestinal tract (Midgley et al., 1992) and the respiratory tract (Ravn-Jonsen et al., 1992) . After inhalation exposure (150 ppm for 8 h), the elimination of unchanged NMP in plasma was a zero order reaction both in nonpregnant and pregnant rats. The volume of distribution was estimated to be 0.7 l/kg (Ravn-Jonsen et al., 1992) . After an intravenous administration of [ 14 C]NMP (45 mg/kg), radioactivity was extensively distributed to all major organs (Wells and Digenis, 1988) . About 80% of the radioactivity administered was excreted in the first day after dosing. The major metabolite, which represented 70 to 75% of the administered dose, was identified later as 5-hydroxy-N-methylpyrolidone (5-HNMP) (Wells et al., 1992) . In the first hours after oral or dermal exposure, unchanged NMP accounted for most of the radioactivity in the plasma. The half-life of unchanged NMP in the plasma was estimated to be 9 to 12 h.
After experimental inhalation exposure (10 to 50 mg/m 3 , 8 h) in human volunteers, the concentration of unchanged NMP in the plasma was maximum at the end of the exposures and declined thereafter, following a nonlinear pattern (Akesson and Paulsson, 1997) . The mean plasma half-life was estimated to be 4 h. Unchanged NMP excreted in the urine during and 44 h after exposure accounted for about 2% of the calculated inhaled dose, and the urinary mean half-life was 4.5 h. 5-HNMP (94 mg/l) and 2-hydroxy-methylsuccinimide (2-HNMS) (6.7 mg/l) were also present in the urine at the end of an 8-h exposure at 25 mg/m 3 (Jonsson and . Plasma and urinary half-life was about 6 to 8 h (Akesson and Jonsson, 2000) . Similar half-life was calculated for N-methylsuccinimide after an 8-h NMP exposure (Jonsson and Akesson, 2001 ). After oral administration of 100 mg to volunteers, unchanged NMP was only detected in the urine during the first day and represented 0.8% of the administered dose . 5-HNMP was excreted in the urine during the first two days with a half-life of about 4 h and represented 44% of the dose. 2-HNMS was detected for 6 days and accounted for 20% of the dose with a half-life of 17 h. N-Methylsucinimide (NMS), which was excreted in the urine over the first 3 days, was a minor metabolite (0.4% of the dose). The increasing half-lives of NMP Ͻ 5-HNMP Ͻ NMS Ͻ 2-HNMS suggest the existence of a metabolic pathway in which NMP is first hydroxylated to 5-HNMP and then oxidized to NMS, which in turn is hydroxylated to 2-HNMS . It has been shown from the radioactivity measured in excreta that between 73 and 82% of a topical application dose of NMP in mixture with 2-vinylpyrrolidone was absorbed through rat skin (Midgley et al., 1992) . The percutaneous absorption rate was calculated by the authors to be 25.3 g/cm 2 /h. In contrast, the percutaneous absorption rate was determined to be 3 orders of magnitude higher in human skin (Ursin et al., 1995) . This latter value seems more realistic as NMP is known to enhance the absorption of different compounds through the skin (Priborsky et al., 1988) .
A zero order and a nonlinear elimination of unchanged NMP in rats and human plasma, respectively, suggests a saturable NMP elimination process. Thus, this study was carried out to confirm this hypothesis. To achieve this, the toxicokinetics of NMP and its main metabolites in plasma and urine were determined at different intravenous doses (0.1 to 500 mg/kg).
Materials and Methods

Chemicals. Radiolabeled N-[
14 C]methylpyrrolidone ([ 14 C]NMP) was supplied by Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK). Radiochemical purity exceeding 99% was determined by HPLC before each dosing. The specific activity was 1.04 GBq/mmol (28 mCi/mmol). Unlabeled NMP, 2-HNMS, and NMS with a purity of Ͼ98% were purchased from Sigma-Aldrich Chimie S.A.R.L (Saint-Quentin Fallavier, France). All the other reagents and chemicals were obtained from commercial sources at the highest purity available. 5-HNMP was synthesized according to Hubert et al. (1975) .
Animals. Male Sprague-Dawley rats (Iffa Credo, Saint-Germain-surl'Arbresle, France) weighing 250 to 300 g were used for all the studies. The animals were acclimatized to laboratory conditions for at least 4 days prior to initiating the studies in a room with a 12-h light/dark cycle designed to control relative humidity 50 Ϯ 5% and temperature 22 Ϯ 1°C. Commercial food pellets (UAR Alimentation-Villemoison, Epinay-sur-Orge, France) and tap water were available ad libitum.
For the sequential collection of blood and urine, a catheter was introduced into the carotid artery and bladder, respectively, 1 week before intravenous or topical administration of [
14 C]NMP. The catheters (i.d., 0.58 mm; o.d., 0.96 mm) were passed subcutaneously, exteriorized through the back of the neck and inserted into a protective stainless tubing (about 2 g in weight) ligatured firmly to the skin. Urine was excreted by injecting saline solution (2 ml) into the bladder. Blood was collected on heparin.
Toxicokinetics after Intravenous Administration. [ 14 C]NMP in saline solution was administered intravenously (1 ml/kg) into the dorsal vein of the penis of lightly etherized rats. Individual doses of [
14 C]NMP (0.1, 1, 10, 100, and 500 mg/kg) were determined by weighing the syringe before and after each administration. After dosing, the animals (n ϭ 3-6) were immediately placed in individual metabolism plastic cages for urine and feces collection. Additionally, exhaled air from three rats per NMP dosing was collected every 24 h for 72 h. [
14 C]NMP or its volatile [ 14 C] metabolites and 14 CO 2 were collected by extracting the air from the individual metabolism glass cages through a series of two water traps and a trap containing 100 ml of Carbosorb (PerkinElmer Life Sciences, Boston, MA) respectively.
At the end of the collection period, the animals were sacrificed by bleeding the abdominal aorta under mild ether anesthesia. The carcass was solubilized in 20% aqueous potassium hydroxide solution. Samples were frozen (Ϫ20°C) until measurement of total radioactivity and NMP metabolite analysis by HPLC.
In Vitro Metabolism of [ 14 C]NMP. A first experiment was conducted to determine the Michaelis-Menten parameters of NMP hydrolysis in microsomes. The microsomes were prepared from the liver of control male rats (250 g). The liver (12 g) was homogenized in an ice-cold mixture (1:2, w/v) of phosphate buffer (0.01 M, pH 7.4) and KCl (0.15 M) and immediately TABLE 1
Mass balance of total radioactivity 72 h after a single intravenous administration of [ 14 C]NMP to male rats
Values are expressed as mean Ϯ sem (n ϭ 5-6, excepted for radioactivity in CO 2 and H 2 O traps and recovery where n ϭ 3). 
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at ASPET Journals on October 14, 2017 dmd.aspetjournals.org centrifuged at 9000g for 15 min at 5°C. The S9 fraction was centrifuged at 100,000g for 1 h. The microsomal fraction was stored at Ϫ80°C for up to 8 weeks. Protein concentration (Lowry method; Lowry et al., 1951) was 16.5 mg/ml and about 1.2 g of fresh liver/ml. The metabolization step used a mixture of microsomal fraction (200 l, 3.3 mg of protein) and phosphate buffer (50 l, 0.01 M, pH 7.4), NADPH (100 l, 40 mM). The reactions were initiated by adding 150 l of [ 14 C]NMP (5500 Bq, 0.625 to 20 mM). The tubes were closed with screw plugs. After vortex mixing for 5 s, the mixture was incubated at 37°C for 15 min with constant shaking. Enzymatic reactions were stopped by adding 10 l H 2 SO 4 at 10% (v/v). The incubates were analyzed by HPLC.
A second experiment was conducted to compare the NMP hydrolysis rate in the S9 fraction of liver from a control rat and a rat dosed with unlabeled NMP (0.1, 1, 10 mg/kg). Saline solution was administered intravenously to one control rat and NMP to exposed rats 5 h before sacrifice. The liver was collected to prepare the S9 fractions. NADPH and [
14 C]NMP (5.3 M) were introduced into 300 l of each S9 fraction (1 mg of protein/ml). After incubation (1 h), the radioactivity contained in the incubates was analyzed by HPLC. Analysis of Radioactivity. Samples of urine (500 -1000 l) and plasma (500 l) were accurately weighed and added directly to liquid scintillation vials containing 10 ml of liquid scintillation solution (Pico Fluor 30; PerkinElmer Life Sciences). Samples of fresh feces were weighed and homogenized in water (1:5, w/v) in glass vials. Tissues (liver or kidney) were homogenized in water (1:5, w/v). Aliquots of feces or tissue homogenates (250 -500 mg) were mixed with 10 ml of Pico Fluor 30. The radioactivity of all the samples was measured in a Packard liquid scintillation spectrophotometer model 1900. Counting efficiency was determined by quenching the correction curves of the various additions and scintillation fluids.
HPLC Analysis of [ 14 C]NMP.
Proteins from an aliquot of plasma (50 to 200 l) were precipitated in methanol (2000 l) at Ϫ20°C for 1 h. After centrifugation (2,500g, 10 min), the precipitate was washed twice with 500 l of methanol. The methanolic phases were pooled and concentrated to about 100 to 200 l under a nitrogen flux at 80°C. The radioactivity contained in 100 l of the methanolic concentrate from plasma or of the supernatant from urine (12,000g, 1 min) were analyzed by HPLC. The HPLC system used comprised a Waters 717 ϩ autosampler (Waters, Milford, MA), a Waters 501 isocratic pump, a Waters 490E UV detector set at 263 nm, and a styrene divinylbenzene column (4.5 ϫ 250 mm, Sugar SH 1011, Shodex; Showa Denko K.K., Tokyo, Japan).
After injection of the sample, the column was eluted for 15 min with solvent A (H 2 S0 4 , 0.001 N) at a flow rate of 0.8 ml/min. A gradient was then run from solvent A to solvent B (H 2 S0 4 , 0.001 N-acetonitrile, 85:15, v/v) for 5 min, followed by isocratic elution with solvent B for 30 min. The eluates were monitored at 263 nm. The radioactivity contained in the HPLC eluates was measured on line with a liquid scintillation spectrophotometer (Flo-One; PerkinElmer Life Sciences) or in fractions (0.4 ml) with a model CA 1900. More than 99% of the radioactivity applied to the HPLC column was recovered in the eluates. The HPLC retention times of the radioactive peaks were compared with the retention times of authentic standards (NMP, 5-HNMP, 2-HNMS, NMS) treated in the same manner.
Expression of Data and Statistical Analysis. Values were expressed as the percentage of [
14 C]NMP dose per organ (% Qo/organ) or as the percentage of [
14 C]NMP dose per g (% Qo/g) of fresh tissue. The one-way analysis of variance test was used to determine the significance of the means. The level of significance was set at p Ͻ 0.05. The toxicokinetics parameters in plasma and urine were calculated by an urinary clearance method (InnaPhase software, Philadelphia, PA).
Enzymatic parameters for NMP metabolism were calculated by a nonlinear regression method (DNREASY software version 3.78 from Duggleby and Leonard, 1998) . The hydrolysis speed of NMP in vivo were determined from the plasma disappearance of NMP over the 0.25 to 3 h period multiplied by the V d of the compound minus the urinary elimination rate.
The terminal elimination rate (␤) of NMP and its main metabolites in plasma were obtained by log-linear concentration time data. The area under the plasma curves of NMP and its metabolites from time 0 to the end of the experiment (AUC 0-t) were calculated by the linear trapezoidal rule. The AUC from infinity was estimated by the calculated concentration at t divided by (␤). The sum of both areas was AUC (0-inf). Clearance (Cl) was the administered dose divided by the AUC (0-inf). Table 1 shows the mass balance radioactivity 72 h after a single intravenous administration of [ 14 C]NMP (0.1, 1, 10, 100, or 500 mg/kg). The total radioactivity excreted in the urine over 3 days (85.4 Ϯ 1.2% of the dose, n ϭ 27) or in the feces (3.4 Ϯ 0.2% of the dose) was independent of the administered dose. However, urinary excretion rate was about 2-and 4-fold lower over the 4 to 8 h period after administration of the 100 and 500 mg/kg doses, respectively, compared with the 0.1 to 10 mg/kg doses. Pulmonary excretion of 14 C was low at the lowest dose but increased gradually with increasing doses and accounted for more than 2% of the two highest doses.
Results
Toxicokinetics Parameters after Intravenous Administration.
The kinetics of unchanged NMP and its main metabolites (5-HNMP, NMS, 2-HNMS) in the plasma after a single intravenous administration of 0.1 mg/kg of [ 14 C]NMP are shown in Fig. 1 . The V d for the central compartment represents 67 to 71% of body weight (Table 2) . Unchanged NMP in the plasma accounted for more than 94% of the total radioactivity over the first 2 h after dosing. During this period, the reduction in NMP was low and linear with time. Thus, the decrease in body burden was calculated to be 7.5% of the dose per hour. Three hours after administration, unchanged NMP in the plasma declined rapidly and exponentially. The half-life was 0.77 Ϯ 0.04 h ( Table 2 ). The plasma levels of 5-HNMP, NMS, and 2-HNMS were higher than the limit of quantification (0.002% of the dose/ml) 1.5, 3, and 4 h after administration of [
14 C]NMP, respectively. The maxi- 
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at ASPET Journals on October 14, 2017 dmd.aspetjournals.org Downloaded from mum levels of 5-HNMP or NMS and 2-HNMS occurred 4 and 6 h after administration of NMP, respectively. The half-life of 5-HNMP in the terminal phase was 2.1 h. After an equilibrium period (60 min) of [ 14 C]NMP (1 M to 4.5 mM) in the plasma of rats, more than 99.5% of the radioactivity was ultra-filtrated through a membrane, which had a cut off of 30,000 Da in plasma (results not shown). This last result indicated a low plasma protein binding of NMP.
The urinary excretion rate of unchanged NMP was maximum during the first 0.5-h period of collection (2.6 Ϯ 1.3% of the dose/h) (Fig. 2) . The unchanged NMP was mainly excreted in the first 6 h, and the urinary clearance was 0.05 ml/min. The urinary excretion rate of 5-HNMP and the other metabolites increased progressively with time. Their maximal excretion rate occurred between 5 and 6 h for 5-HNMP and 5 and 10 h for NMS and 2-HNMS. The urinary half-life and clearance of 5-HNMP were 2.9 h and 1.0 ml/min, respectively.
The time course profiles of NMP and 5-HNMP in plasma were very similar for the three lowest doses (0.1, 1, 10 mg/kg). In contrast, for the two highest doses, both NMP and 5-HNMP in the plasma declined slowly during the first 10 h after administration (results not shown). Similarly, at the highest dose, the urinary excretion rate of 5-HNMP was constant over the 8 to 24 h period and was 3-fold lower than at the lowest doses, accounting for 2.5% of the dose per hour (3.5 mg Eq/h) (result not shown).
Metabolic Rate of NMP. The metabolic rate of NMP was determined from the disappearance of NMP from the plasma after the distribution phase minus the urinary excretion rate. The estimation of the Michaelis-Menten constants K m and V m is 2.0 mM and 634 nmol/min (3.8 mg/h) for a rat weighing 250 g (Fig. 3a) .
The HPLC chromatogram of the radioactivity contained in the microsomes of rat liver incubated with [
14 C]NMP (0.625 to 20 mM) revealed two peaks corresponding to unchanged NMP and 5-HNMP (result not shown). The Michaelis-Menten constants K m and V m were 5.1 Ϯ 0.4 mM and 0.28 Ϯ 0.2 nmol/min/mg of protein (Fig. 3b) . The latter value corresponds to about 36 nmol/min for a rat weighing 250 g.
The quantities of 5-HNMP produced after incubation of [ 14 C]NMP in the S9 fraction of the liver of the control rat and rat exposed to NMP (0.1, 1, 10 mg/kg, intravenous administration) 5 h before sacrifice were very similar and correspond to about 0.1 nmol/min for a 250 g rat (results not shown).
Discussion
The results of this study confirm that NMP is extensively metabolized and rapidly excreted in urine. Thus, about 86% of the admin- Values are expressed as mean Ϯ S.E.M. (n ϭ 5). LOD and LOQ are the limits of detection and quantification, respectively. E, 14 C; f, NMP; OE, 5-HNMP; ϫ, NMS.
istered [ 14 C] activity was excreted in the urine 72 h after a single intravenous administration (0.1 mg/kg to 500 mg/kg of [ 14 C]NMP), and 90% of the total radioactivity recovered in the urine was excreted within 1 day of being administered. The volume of distribution was 70% of body weight, which corresponds to the total aqueous volume of the animal. These results are in accordance with earlier animal studies (Wells and Digenis, 1988; Ravn-Jonsen et al., 1992) .
In the first hour after a single i.v. administration, unchanged NMP represented more than 90% of the plasma radioactivity, as observed after oral and dermal administration (Midgley et al., 1992) . For the three lowest doses (0.1, 1, and 10 mg/kg), after an initial fast distribution phase, unchanged NMP declined linearly with time until 3 h after administration. It then declined exponentially with a half-life of 0.8 h. This value is about 10 times lower than the value determined after intravenous administration of 45 mg/kg (6 to 9 h) (Wells and Digenis, 1988) . This discrepancy may be the result of the high dosage and the protocol design in the previous study. This author measured the NMP level in the plasma of the rats until 6 h after administration of the toxicant. During this period, if the drop in unchanged NMP of a 10, 100, or 500 mg/kg dose is fitted by an exponential function, the slope will give also an apparent half-life of about 7 h. The slow decline in unchanged NMP was attributed to release from a deep compartment or a storage depot, such as fat. However, the decline in unchanged NMP was approximately linear with time until 24 h at the two highest doses tested in the present paper (100 and 500 mg/kg). This decline in unchanged NMP can be explained by a NMP metabolic saturation step. The values of Michaelis-Menten constant calculated from the plasma concentrations of unchanged NMP and determined in vitro from liver microsomes are very similar, corresponding to 2.0 and 5.1 mM, respectively. At the highest dose, the concentration of unchanged NMP was 5 mM, roughly the same as the K m values. Moreover, the rate of disappearance of unchanged NMP was 2.6 mg/h, which is in accordance with the V m value determined from the in vivo results (3.8 mg/h). However, this V m value is about 20 times higher than that estimated from the in vitro experiment (0.2 mg/h). The 20-fold differences between the in vitro and in vivo calculated V m could be the consequence of an extra-hepatic metabolism. The metabolic saturation step could explain the zero order reaction for the elimination of unchanged NMP in the plasma of nonpregnant and pregnant rats after inhalation exposure (150 ppm over 8 h) (Ravn-Jonsen et al., 1992) .
A metabolic saturation step does not explain the linear decline in unchanged NMP observed during the first 3 h after administration of the 0.1 to 10 mg/kg doses. For these three doses, all the toxicokinetics 
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at ASPET Journals on October 14, 2017 dmd.aspetjournals.org parameters are very similar. Additionally, the unchanged NMP concentrations in the plasma were very low (0.001 to 0.095 mM) compared with the value of K m (Ͼ 2 mM). Moreover, for the first 3 h after administering the NMP, 5-HNMP levels in plasma were very low and then increased to a maximum, after which the decrease in unchanged NMP followed an exponential function. From the ex vivo experiment, it is unlikely that these findings were the consequence of an enzyme induction. Indeed, the metabolic rates of 5-HNMP formation in the S9 fraction of liver from rats pretreated or not with NMP were not significantly different.
Unchanged NMP was not bound to plasma proteins and only 4 to 5% of the dose was excreted in the urine for the lowest administered doses of NMP. The low urinary clearance of NMP indicates intensive tubular reabsorption of the compound. In contrast, clearance of 5-HNMP (1 ml/min), similar to inulin clearance, suggests a simple glomerular filtration of the metabolite. 5-HNMP is the main urinary metabolite of NMP. Total urinary excretion accounted for 42 to 45% of the administered doses (0.1 to 10 mg/kg), which is similar to the value obtained in human volunteers after oral administration of 100 mg/kg and after inhalation exposure 2000) . For the two highest doses, more than the half of the dose administered was excreted as 5-HNMP in the urine. This latter value is lower than the total excretion rate observed after intravenous administration in rats, in which 75% of the dose was excreted as 5-HNMP (Wells et al., 1992) .
In conclusion, unchanged NMP is intensively reabsorbed by the glomerule, and its metabolism follows a saturable process.
